WHO vaccine-preventable diseases: monitoring system. 2013 global summary

Last updated 20-Octl-2013 (data as of 16-Oct-2013)
Next overall update June 2014
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 12'6701 Infant (under 12 months) mortality rate: 52
GDP / capita (US$): 21'9031 Child (under 5 years) mortality rate: 62

Population data in thousands3

  2012  2011  2010  2009  2008  2000  1990  1980 
Total population 38'211  38'205  38'199  38'194  38'190  38'351  38'150  35'641 
Births 411  409  405  400  394  372  554  695 
Surviving infants 409  407  403  398  392  369  545  680 
Pop. less than 5 years 2'066  2'041  1'972  1'930  1'880  1'993  2'898  3'263 
Pop. less than 15 years 5'721  5'729  5'733  5'795  5'874  7'425  9'560  8'603 
Female 15-49 years 9'371  9'433  9'509  9'587  9'671  10'134  9'384  9'127 

Number of reported case

(Click for retrospective incidence data for Poland)
Diphtheria
Japanese encephalitis
Measles 71  13  115  77  56'471  24'882 
Mumps 2'779  2'754  2'954  17'548 
Pertussis 4'682  1'266  2'390  2'269  292  232 
Polio*
Rubella 6'263  4'196  7'586  46'181 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total) 19  16  19  14  65  89 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Poland)
Vaccine year result method % card seen                                                
BCG          94  93  94  96  97  93 
DTP1         
DTP3          99  99  99  98  96  96 
HepB_BD          95 
HepB3          97  98  98  99 
Hib3          99  99  99 
JapEnc         
MCV          98  98  98  97  95  92 
MCV2          95  94  95  96 
PCV1         
PCV3         
Pol3          95  96  96  98  96  96 
Rota1         
Rota_last         
Rubella1          98  98  98 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2014

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Poland)
BCG 93  93  93  94  94  96  97  93 
DTP1 99  99  99  99  99  99  98  98 
DTP3 99  99  99  99  99  98  96  96 
HepB3 98  98  98  98  98  99 
Hib3 99  99  99  99  94 
MCV 98  98  98  98  98  97  95  92 
PCV3
Pol3 96  96  96  96  98  98  96  96 
Rota_last

Number of districts in the country 379  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
 

Immunization Schedule (2012 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTwP 7-8 weeks; 3-4, 5-6, 16-18 months; Yes
HepB birth; 2, 7 months; Yes
Hib 2, 3-4, 5-6, 16-18 months; Yes
IPV 3-4, 5-6, 16-18 months; Yes
MMR 13-14 months; 10 years; Yes
OPV 6 years; Yes
Td 14, 19 years; Yes
TdaP 6 years; Yes

Immunizaton indicators

Indicator Expected answer 2012  2011  2010  2009  2008  2007  2006 

Planning and management

Multi-year plan (MYP) for immunization Yes/No/NR No    No  No    No  No 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number     320      16  NA 

National Immunization Advisory Mechanism

Does the country have a standing technical advisory group on immunization? Yes/No/NR Yes    No         

System performance

Total number of districts in country number 379    379  379    379  379 
Nº districts with DTP3 coverage >=80% number              
% of districts with DTP3 coverage >=80% From 0 to 100%              
Nº districts with measles (MCV1) coverage >=95% number              
% of districts with MCV1 coverage >=95% From 0 to 100%              

Safety

Monitoring of Adverse Events Following Immunization (AEFI)? Yes/No/NR Yes    Yes  Yes    Yes  Yes 
Does your country have a vaccine adverse events review committee? Yes/No/NR/ND     No         

Finance

Percentage of routine vaccines funded by Government From 0 to 100% 100    100      100  100 

Maternal and neonatal tetanus (NT) elimination

NT eliminated Yes/No Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2012, data for 2011
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.